56 results
8-K
EX-2.2
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
exclusivities, of such product, and the regulatory environment and other relevant technical, commercial, legal, scientific and/or medical factors
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
business in the then-current environment, including the macro-economic, industry and market conditions negatively impacting gene therapy companies … to Orchard at attractive valuations in the then-current economic environment that would not be significantly dilutive to existing Orchard shareholders
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
of operating Orchard’s business in the then-current environment, including the macro-economic, industry and market conditions negatively impacting gene … sufficient equity financing to Orchard at attractive valuations in the then-current economic environment that would not be significantly dilutive to existing
DEFA14A
ORTX
Orchard Therapeutics plc
17 Oct 23
Additional proxy soliciting materials
4:32pm
on capital markets as a primary source of funding, which as you know has been a difficult financing environment of late.
As a combined entity, we look forward
DEFA14C
bhxib5f3glzwqw4a1
5 Oct 23
Additional information
4:43pm
DEFA14A
0p3nw2t7z 46
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-2.1
a76zi3 or
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
424B3
5lyls55bgri2cr5jyob
21 Aug 23
Prospectus supplement
4:32pm
8-K
EX-99.1
kbwd5ns39bmbx8cx9m3b
23 May 23
Regulation FD Disclosure
7:06am
8-K
EX-1.1
7fm vh9irqz69k
6 Oct 22
Entry into a Material Definitive Agreement
4:34pm